Tisagenlecleucel infusion in patients with relapsed/refractory ALL and concurrent serious infection

BACKGROUND: Tisagenlecleucel, an anti-CD19 chimeric antigen receptor T (CAR-T) cell therapy, has demonstrated durable efficacy and a manageable safety profile in pediatric and young adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) in the ELIANA pivotal trial and re...

Descripción completa

Detalles Bibliográficos
Autores principales: Hall, Erin M, Yin, Dwight E, Goyal, Rakesh K, Ahmed, Atif A, Mitchell, Grace S, St. Peter, Shawn D, Flatt, Terrie G, Ahmed, Ibrahim A, Li, Weijie, Hendrickson, Richard J, August, Keith J, Myers, G Doug
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7818837/
https://www.ncbi.nlm.nih.gov/pubmed/33472856
http://dx.doi.org/10.1136/jitc-2020-001225

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7818837/
https://www.ncbi.nlm.nih.gov/pubmed/33472856
http://dx.doi.org/10.1136/jitc-2020-001225

Ejemplares similares